Response and incidence of graft-versus-host disease after treatment with bulk or escalating dose donor lymphocyte infusion
| . | Donor Lymphocyte Infusion Dose Regimen . | |
|---|---|---|
| Bulk (n = 28) . | Escalating (n = 20) . | |
| Probability of cytogenetic remission at 2 years (95% CI) | 67% (49%-83%) | 91% (63%-98%) |
| GVHD | ||
| Acute | ||
| Grade 0 | 10* (37%) | 15 (75%) |
| Grade 1 | 5* (19%) | 3 (15%) |
| Grade 2 | 5* (19%) | 2 (10%) |
| Grades 3-4 | 7* (26%) | 0 (0%) |
| Chronic | ||
| Non/limited | 15*,† (59%) | 17‡ (89%) |
| Extensive | 11*,† (41%) | 2‡ (11%) |
| . | Donor Lymphocyte Infusion Dose Regimen . | |
|---|---|---|
| Bulk (n = 28) . | Escalating (n = 20) . | |
| Probability of cytogenetic remission at 2 years (95% CI) | 67% (49%-83%) | 91% (63%-98%) |
| GVHD | ||
| Acute | ||
| Grade 0 | 10* (37%) | 15 (75%) |
| Grade 1 | 5* (19%) | 3 (15%) |
| Grade 2 | 5* (19%) | 2 (10%) |
| Grades 3-4 | 7* (26%) | 0 (0%) |
| Chronic | ||
| Non/limited | 15*,† (59%) | 17‡ (89%) |
| Extensive | 11*,† (41%) | 2‡ (11%) |
CI, confidence interval; GVHD, graft-versus-host disease; DLI, donor lymphocyte infusion.
GVHD data for 1 patient are unknown.
One patient died of grade 4 acute GVHD 46 days after DLI and could not be evaluated for response or chronic GVHD.
The follow-up of 1 patient was too short from DLI (<5 months) to evaluate chronic GVHD.